Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | TPH1 | P17752 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469220 | 1.00 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23069024 | 0.85 | NOS3 (0.55) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23069027 | 0.85 | NOS3 (0.55) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL22669502 | 0.84 | GRIK1 (0.46) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL15511517 | 0.82 | SLC7A5 (0.41) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL29373039 | 0.82 | SLC7A5 (0.41) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL15469201 | 0.82 | SLC7A5 (0.41) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL15469207 | 0.82 | HSD17B10 (0.47) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL20339315 | 0.82 | HSD17B10 (0.47) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL15469227 | 0.81 | HSD17B10 (0.42) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540197-B2 | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2026-02-03 | — | — | US | claimed |
| US-12427201-B2 | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2025-09-30 | — | — | US | claimed |
| US-20250236674-A9 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2025-07-24 | — | — | US | claimed |
| EP-4588521-A2 | POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS | VAXCYTE, INC. (US) | 2025-07-23 | — | — | EP | claimed |
| US-20250230198-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING PROTEIN NANOWIRES WITH TUNABLE FUNCTIONALITY | YALE UNIVERSITY | 2025-07-17 | — | — | US | claimed |
| CN-120076831-A | Anti-ROR 1 antibodies and antibody conjugates, compositions comprising anti-ROR 1 antibodies or antibody conjugates, and methods of making and using anti-ROR 1 antibodies and antibody conjugates | 苏特罗生物制药公司 | 2025-05-30 | — | — | CN | claimed |
| EP-4547284-A1 | ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-ROR1 ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES | Sutro Biopharma, Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250135025-A1 | ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2025-05-01 | — | — | US | claimed |
| EP-3562503-B1 | POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS | VAXCYTE INC (US) | 2025-04-23 | — | — | EP | claimed |
| US-20250122306-A1 | ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-TISSUE FACTOR ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2025-04-17 | — | — | US | claimed |
| WO-2018126229-A9 | POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS | SUTROVAX, INC. (US) | 2019-07-25 | — | — | WO | claimed |
| US-20190144546-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2019-05-16 | — | — | US | claimed |
| WO-2019055909-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | SUTRO BIOPHARMA, INC. (US) | 2019-03-21 | — | — | WO | claimed |
| WO-2019055931-A1 | ANTI- FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | SUTRO BIOPHARMA, INC. (US) | 2019-03-21 | — | — | WO | claimed |
| US-20190083641-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2019-03-21 | — | — | US | claimed |
| WO-2019023316-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | SUTRO BIOPHARMA, INC. (US) | 2019-01-31 | — | — | WO | claimed |
| US-20180333484-A1 | Polypeptide-Antigen Conjugates with Non-Natural Amino Acids | SUTROVAX, INC. (US) | 2018-11-22 | — | — | US | claimed |
| WO-2018126229-A2 | POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS | SUTROVAX, INC. (US) | 2018-07-05 | — | — | WO | claimed |
| EP-3271359-A1 | ISOQUINOLIDINOBENZODIAZEPINES | Cellerant Therapeutics, Inc. (US) | 2018-01-24 | — | — | EP | claimed |
| WO-2016149546-A1 | ISOQUINOLIDINOBENZODIAZEPINES | CELLERANT THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427201-B2 | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates | FOLR1, FOLR2, DHFR | SLC7A5 743/4885PTGS1 4083/4885ALPI 2698/4885 |
| US-20180333484-A1 | Polypeptide-Antigen Conjugates with Non-Natural Amino Acids | CD74, DNPEP, NGLY1 | SLC7A5 227/4885PTGS1 3633/4885ALPI 1709/4885 |
| US-12540197-B2 | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates | VSIG8, F13B, HNRNPH3 | SLC7A5 1194/4885PTGS1 4003/4885ALPI 2042/4885 |
| US-20190083641-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | FOLR1, FOLR2, DHFR | SLC7A5 743/4885PTGS1 4083/4885ALPI 2698/4885 |
| US-20250135025-A1 | ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATES | ROR1, RORA, RORB | SLC7A5 3822/4885PTGS1 4254/4885ALPI 661/4885 |
| US-20250236674-A9 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | SLC7A5 2691/4885PTGS1 4826/4885ALPI 1470/4885 |
| US-20250122306-A1 | ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-TISSUE FACTOR ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATES | F3, F13B, SERPINA6 | SLC7A5 3468/4885PTGS1 1557/4885ALPI 1651/4885 |
| US-20190144546-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD99, CD63 | SLC7A5 427/4885PTGS1 4801/4885ALPI 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.